WallStSmart

Gossamer Bio Inc (GOSS)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 1151% more annual revenue ($606.42M vs $48.47M). GOSS leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

GOSS

Hold

39

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GOSS1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
47.1%10/10

Revenue surging 47.1% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

GOSS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$99.14M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-7.8%2/10

ROE of -7.8% — below average capital efficiency

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GOSS

The strongest argument for GOSS centers on Revenue Growth. Revenue growth of 47.1% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : GOSS

The primary concerns for GOSS are EPS Growth, Market Cap, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

GOSS profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

GOSS carries more volatility with a beta of 2.11 — expect wider price swings.

GOSS is growing revenue faster at 47.1% — sustainability is the question.

GOSS generates stronger free cash flow (-48M), providing more financial flexibility.

Bottom Line

GOSS scores higher overall (39/100 vs 39/100) and 47.1% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Gossamer Bio Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?